HORIBA Medical supports community-based near-patient testing for treatment resistant schizophrenia patients

HORIBA Medical supports community-based near-patient testing for treatment resistant schizophrenia patients

Award winning partnership between Britannia Pharmaceuticals, HORIBA Medical and Northumberland Tyne & Wear Mental Health Trust for clozapine dispensing

Northampton, UK – 9^th October 2020 – HORIBA UK Ltd, Medical has recently received recognition for a new partnership with Britannia Pharmaceuticals and Northumberland Tyne & Wear Mental Health Trust (NTW) for community-based near-patient testing for treatment resistant schizophrenia patients.

Highly commended within the ‘Best Healthcare Provider Partnership with the NHS’ category at the recent HSJ Partnership Awards, the installation of HORIBA’s Yumizen H500 point-of-care haematology analysers at 14 of its mental health clinics has enabled NTW to significantly improve its model for clozapine dispensing. Schizophrenia patients now have an effective ‘one-stop shop’ for blood testing and dispensing, with improved patient outcomes evident.

Clozapine, supplied as Denzapine by Britannia Pharmaceuticals, is indicated in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics. Denzapine is also indicated in psychotic disorders occurring during the course of Parkinson's disease, in cases where standard treatment has failed.

This prescription medicine can cause agranulocytosis resulting in serious infections and even death. Therefore, prior to treatment initiation, physicians must ensure, to the best of their knowledge, that the patient has not previously experienced an adverse haematological reaction to clozapine that necessitated its discontinuation. Prescriptions should not be issued for periods longer than the interval between two blood counts.

Before clozapine can be dispensed, white blood cell count (WBC) and an absolute neutrophil count (ANC) are required to ensure patient safety. NTW clinics operate a traffic light dispensing system meaning that patients not having a blood test or without a confirmed sufficiently high WBC or high ANC cannot receive their clozapine prescription. This can cause subsequent stress and anxiety for the patient.

Having the Yumizen H500 delivering a full blood count with 5-part WBC differential from just 20μL of whole blood within two minutes at the NTW clinics, has helped to alleviate stress, as more patients can now receive their prescription immediately in a single visit to the clinic. Furthermore, as the Yumizen H500 can analyse capillary blood samples obtained by a simple finger prick, this can be used as a last resort as an easier means of taking blood from mental health patients who may be particularly anxious or drug users.

“Previously patients would have to attend clinic at least twice to obtain their clozapine. Once to have their blood taken, then the sample would be sent by post to the main lab, meaning they would then have to return to pick up their prescription a few days later,” explained Carolyn Gahgan, Mental Health Liaison Manager, Britannia Pharmaceuticals. “Having to travel and attend clinic can be particularly stressful for mental health patients, so being able to set up a ‘one-stop shop’ has proved a real game changer for the Trust and its patients.”

The HSJ Partnership Awards celebrate the most effective partnerships with the NHS and highlight the benefits which working with the private and third sectors can bring to patients and NHS organisations.

For more information on HORIBA UK Ltd. Medical and its products, please visit: www.horiba.com/uk/medical.

This press release is available online at: https://www.horiba.com/uk/medical/news-events/news/article/horiba-medical-supports-community-based-near-patient-testing-for-treatment-resistant-schizophrenia-patients-66801/

- ENDS –

Editors’ notes

ABOUT HORIBA UK Ltd - Medical:

www.horiba.com/uk/medical

Resulting from over 30 years of understanding and meeting its customers’ individual needs, the HORIBA UK Ltd Medical team holds a wealth of expertise and is a well-respected and renowned specialist in the design, manufacture and support of automated in vitro diagnostic systems.

HORIBA Medical facilitates the entire analytical process, both in the laboratory and at the point of care, from process and analyser optimisation, analysing samples and managing data to remote monitoring and e-Learning. Furthermore, in addition to NHS and private healthcare settings, HORIBA Medical products are proving their worth in many other areas, including: sports science, food and beverage, pharma and nutraceuticals, and clinical research.

HORIBA Medical’s product and service combinations all deliver quality results, flexibility, security and process efficiency.  These merits in turn ensure effective clinical decision making, enhanced patient care pathways and improved patient outcomes.